OQROGet OQRO Pro
Insider trade

Abbott Laboratories (ABT)Director bought ~$542K

Daniel J Starks, Director at Abbott Laboratories, bought ~$542K of Abbott Laboratories shares.

~$542K
Approx. value · 4,967 sh @ $109.14
6.73M
Holds after · shares reported
Traded
Feb 4, 2026
Filed
Feb 6, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 23, 2024CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  2. Nov 5, 2025CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  3. Nov 13, 2025CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
  4. Nov 18, 2025CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  5. Dec 4, 2025Congress · 1 personMembers of Congress: 2 sales
  6. Dec 8, 2025CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  7. Dec 12, 2025Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year“On December 12, 2025, Nita Ahuja, M.D. was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.”
  8. Dec 17, 2025FDAFDA device clearance: Amplatzer Piccolo™ Delivery System (9-PDS-04F-045)
  9. Dec 18, 2025FDAFDA device clearance: Assert-IQ (DM5100)
  10. Dec 18, 2025CongressDisclosed sale of ABT — reported range $1,001 - $15,000
  11. Dec 19, 2025FDAFDA device approval: Volt™ PFA System
  12. Dec 19, 2025CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
  13. Jan 22, 2026Company filing · Form 8-K · ResultsReported its results
  14. Jan 23, 2026Insider · First insider buy since Feb 2021CEO purchased ~$2.01M of ABT shares in the open market
  15. Jan 29, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  16. Feb 4, 2026 · this disclosureInsider · First buy since 2018Director purchased ~$542K of ABT shares in the open market

What came next

  1. Feb 4, 2026Insider · First buy since 2018Director purchased ~$545K of ABT shares in the open market
  2. Feb 10, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
  3. Feb 13, 2026FDAFDA device clearance: Armada™ 14 NC PTA Catheter
  4. Feb 20, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
  5. Feb 23, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  6. Mar 2, 2026Insider · 6 peopleInsiders: 6 sales (~$485K)
  7. Mar 9, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  8. Mar 13, 2026FDAFDA device clearance: Amplatzer™ Trevisio™ Intravascular Delivery System; 9-ATV06F45/609-ATV07F45/609-ATV07F45/809-ATV08F45/609-ATV08F45/809-ATV09F45/809-ATV10F45/809-ATV12F45/80
  9. Mar 19, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
  10. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  11. Apr 16, 2026Company filing · Form 8-K · ResultsReported its results
  12. Apr 16, 2026FDAFDA device clearance: Disposable Radiofrequency Cannula
  13. Apr 20, 2026FDAFDA device clearance: EnSite™ X EP System
  14. Apr 23, 2026Insider · 1 day before an 8-KCFO purchased ~$201K of ABT shares in the open market
  15. Apr 24, 2026Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders.”
  16. Apr 24, 2026FDAFDA device clearance: OPTIS Mobile Next Imaging System (1014932); OPTIS Integrated Next Imaging System (1014933); Ultreon 3.0 Software Upgrade Kit (ULTR300001)
  17. Apr 24, 2026FDAFDA device clearance: Amplatzer TorqVue Delivery System
  18. Apr 27, 2026Insider · Their largest buy since 2018Director purchased ~$927K of ABT shares in the open market
  19. Apr 28, 2026FDAFDA device clearance: Anti-HCV Next
  20. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Abbott Laboratories

For Abbott Laboratories, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 82 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.

Other recent filings by Daniel J Starks, Director

The full history of Daniel J Starks, Director is on the profile page.

How this filing works

Other disclosures at Abbott Laboratories

Everything OQRO holds on this company is on its ABT page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data